Piyush Gondaliya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Piyush Gondaliya has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Adil Ali Sayyed
Mayo Clinic
3 shared publications Julia Driscoll
Mayo Clinic
2 shared publications- Rakesh Kumar Tekade
National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Palaj, Opp. Air force station, Gandhinagar-382355, Gujarat, India
2 shared publications - Tushar Patel
Mayo Clinic
2 shared publications - Ayano Kabashima
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester MN, United States; Center for Preventative Medicine, Keio University, Tokyo, Japan
1 shared publication - Brandon Wilbanks
Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA
1 shared publication
Latest Publications
- Open Access
- 17 August 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (9) , 4540-4552
Engineered Natural Killer Cell Derived-Extracellular Vesicles: An Acellular Immunotherapy with Cytotoxic Effects in SNU-1079 Human Cholangiocarcinoma Cells
The use of natural killer (NK) cells for the treatment of solid tumors such as cholangiocarcinoma has been hindered by challenges related to cell production, persistence and trafficking, as well as by reduced efficacy within an immunosuppressive tumor microenvironment. Antitumor immunity can be reduced by the interaction of NK cell expressed programmed cell death protein 1 (PD1) with ligands on tumor and other cells within the tumor microenvironment. The antitumor effect of NK cells is enhanced in cells engineered to express a truncated PD1 without an intracellular domain. The cytolytic potential and therapeutic efficacy of extracellular vesicles (EVs) derived from human NK cells expressing truncated PD1 was evaluated as a cell-free therapeutic to overcome some limitations faced by cell therapies. We demonstrate the feasibility of efficient expansion, production and isolation of therapeutic vesicles from human NK cell lines and from engineered NK92 cells expressing truncated PD1. The cytotoxic efficacy of these therapeutic vesicles was validated in both monolayer tumor cell cultures and in multicellular tumor spheroids. Concomitant administration of gemcitabine upregulated NKG2D ligands on tumor cells and increased susceptibility to NK cell and to NK cell derived EV mediated killing. These findings position engineered NK cell derived-EVs as a scalable and promising cell-free immunotherapeutic for cholangiocarcinoma.
- 17 August 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (9) , 4540-4552
Open AccessEngineered Natural Killer Cell Derived-Extracellular Vesicles: An Acellular Immunotherapy with Cytotoxic Effects in SNU-1079 Human Cholangiocarcinoma Cells
The use of natural killer (NK) cells for the treatment of solid tumors such as cholangiocarcinoma has been hindered by challenges related to cell production, persistence and trafficking, as well as by reduced efficacy within an immunosuppressive tumor microenvironment. Antitumor immunity can be reduced by the interaction of NK cell expressed programmed cell death protein 1 (PD1) with ligands on tumor and other cells within the tumor microenvironment. The antitumor effect of NK cells is enhanced in cells engineered to express a truncated PD1 without an intracellular domain. The cytolytic potential and therapeutic efficacy of extracellular vesicles (EVs) derived from human NK cells expressing truncated PD1 was evaluated as a cell-free therapeutic to overcome some limitations faced by cell therapies. We demonstrate the feasibility of efficient expansion, production and isolation of therapeutic vesicles from human NK cell lines and from engineered NK92 cells expressing truncated PD1. The cytotoxic efficacy of these therapeutic vesicles was validated in both monolayer tumor cell cultures and in multicellular tumor spheroids. Concomitant administration of gemcitabine upregulated NKG2D ligands on tumor cells and increased susceptibility to NK cell and to NK cell derived EV mediated killing. These findings position engineered NK cell derived-EVs as a scalable and promising cell-free immunotherapeutic for cholangiocarcinoma.
- Open Access
- 16 March 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (4) , 101779
Cell-SELEX identifies a DNA aptamer for highly selective in vivo siRNA delivery in cholangiocarcinoma
- 16 March 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (4) , 101779
Open AccessCell-SELEX identifies a DNA aptamer for highly selective in vivo siRNA delivery in cholangiocarcinoma
- 6 April 2023
- Published by Elsevier
- p. 57-95
Role of microRNAs in toxicology
- 28 November 2022
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 11 (3) , 777-790
Lung-on-chip microdevices to foster pulmonary drug discovery
Fostering pulmonary research for managing pulmonary threat requires a potential alternative approach mimicking the in vivo complexities. This review expounds on lung-on-chip microfluidic simulator devices to foster pulmonary drug discovery and personalized medicine.
- 28 November 2022
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 11 (3) , 777-790
Lung-on-chip microdevices to foster pulmonary drug discovery
Fostering pulmonary research for managing pulmonary threat requires a potential alternative approach mimicking the in vivo complexities. This review expounds on lung-on-chip microfluidic simulator devices to foster pulmonary drug discovery and personalized medicine.